

MAIL STOP AMENDMENT Attorney Docket No. 27632U

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

FLOCKERZI

Confirmation No.: 6862

Serial No: 10/591,955

Group Art Unit: 1617

Filed: September 8, 2006

Examiner: MANOHAR, M.

For: NOVEL N-(ALKOXYALKYL) CARBAMOYL-SUBSTITUTED 6-PHENYL-BENZONAPHTHYRIDINE DERIVATIVES AND THEIR USE AS PDE 3/4

INHIBITORS

TRANSMITTAL LETTER

Commissioner for Patents Box 1450

BOX 1450

Alexandria, VA 22313-1450

Sir:

- (1) Transmittal Letter; and
- (2) Response to Restriction/Election Requirement.

The Commissioner is hereby authorized to charge any deficiency or credit any excess to Deposit Account **N**umber 14-0112.

Respectfully submitted,

THE NATH LAW GROUP

Date: January 21, 2009 THE NATH LAW GROUP 112 S. West Street Alexandria, VA 22314

Tel: (703) 548-6284 Fax: (703) 683-8396 Gary M. Nath Reg. No. 26,965 Sheldon M. McGee Reg. No. 50,454 Customer No. 34375



MAIL STOP AMENDMENT Attorney Docket No. 27632U

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

FLOCKERZI

Confirmation No.: 6862

Serial No: 10/591,955

Group Art Unit: 1617

Filed: September 8, 2006

Examiner: MANOHAR, M.

For: NOV

NOVEL N-(ALKOXYALKYL) CARBAMOYL-SUBSTITUTED 6-PHENYL-BENZONAPHTHYRIDINE DERIVATIVES AND THEIR USE AS PDE 3/4

INHIBITORS

RESPONSE TO RESTRICTION REQUIREMENT

MAIL STOP AMENDMENT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This paper is submitted responsive to the Official Action dated December 24, 2008, making a Response due on or before January 24, 2009. As January 24, 2009 is a Saturday, pursuant to MPEP § 710.01(a), this reply is timely if it is filed on the next succeeding business day. As such, this Response is timely filed.

REMARKS

Claims 1-6, 8, 10 and 11 are pending in the captioned application. The Examiner required restriction under 35 U.S.C. §§ 121 and 372, as follows:

Group I:

Claims 1-6 and 8, drawn to compounds of formula 1.

Group II:

Claims 10-11, drawn to a method of treating illness in a

patient by administering a compound of formula 1.